Dinotefuran/Permethrin/Pyriproxyfen

Verify with FDA CVM →

20 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
20
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Dinotefuran/Permethrin/Pyriproxyfen

Administration Routes

TopicalUnknown

Species Affected

Dog 20

Most Affected Breeds

Spitz - German Pomeranian 3
Retriever - Labrador 2
Greyhound - Italian 1
Doberman Pinscher 1
Chihuahua 1
Terrier - Bull - Staffordshire 1
Pug 1
Beagle 1
Spaniel - Springer English 1
Dachshund (unspecified) 1

Most Reported Reactions

Vomiting 8
Other abnormal test result NOS 4
Lethargy (see also Central nervous system depression in 'Neurological') 4
Twitching 2
Diarrhoea 2
Anorexia 2
Shaking 2
Papule 1
Skin lesion NOS 1
Hair loss NOS 1
Agitation 1
Hyperactivity 1

Outcome Breakdown

Recovered/Normal
12 (60.0%)
Ongoing
4 (20.0%)
Outcome Unknown
4 (20.0%)

Data Summary

Metric Value
Total adverse event reports 20
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 1
Distinct breeds in reports 17
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Dinotefuran/Permethrin/Pyriproxyfen Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 20 adverse event reports referencing Dinotefuran/Permethrin/Pyriproxyfen, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Dinotefuran/Permethrin/Pyriproxyfen. Reported administration routes include Topical, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Dinotefuran/Permethrin/Pyriproxyfen reports are Dog (20 reports), with Dog accounting for the largest share. Within those species, Spitz - German Pomeranian (3), Retriever - Labrador (2), Greyhound - Italian (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Dinotefuran/Permethrin/Pyriproxyfen are Vomiting (8), Other abnormal test result NOS (4), Lethargy (see also Central nervous system depression in 'Neurological') (4), Twitching (2). Of the 20 reports with a coded outcome, Recovered/Normal is the leading category at 60.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Dinotefuran/Permethrin/Pyriproxyfen.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial